Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0144471 in C3 Glomerulopathy (Phase 2, 6-month treatment)
2017-000663-33Phase 2Unknown
- Sponsor
- Achillion Pharmaceuticals
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing ACH-0144471 oral treatment with Placebo (2 arms). Primary endpoints: Renal biopsy composite score change and Change in eGFR. Status: unknown.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on 2017-000663-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000663-33.